Grace Hyun
New York, NYNPI 1699829630
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $845,446 of the $851,752 with a category attached, or 99.3%. Veru Inc. accounts for 99.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $734,471 and has fallen 99.9% since, to $455 in 2025.
Across 152 payments — averaging $5603.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veru Inc.$846K
- Alnylam Pharmaceuticals Inc.$2K
- Palette Life Sciences, Inc.$1K
- Biomarin Pharmaceutical Inc.$900
- Boston Scientific$848
- Teleflex LLC$563
- plus $1K from 11 others
What the payments were for
- Speaking & faculty fees$845,44699%
- Travel & lodging$6120%
- Food & beverage$5,6941%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veru Inc. | 8 | $845,510 |
| Alnylam Pharmaceuticals Inc. | 60 | $1,541 |
| Palette Life Sciences, Inc. | 16 | $1,133 |
| Biomarin Pharmaceutical Inc. | 1 | $900 |
| Boston Scientific | 11 | $848 |
| Teleflex LLC | 4 | $563 |
| AbbVie(2 entities) | 19 | $440 |
| Travere Therapeutics, Inc. | 14 | $234 |
| Urogen Pharma, Inc. | 9 | $226 |
| Novo Nordisk | 1 | $122 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $64 |
| Astellas Pharma Global Development | 1 | $55 |
| Merck | 1 | $33 |
| Antares Pharma, Inc. | 1 | $27 |
| Immunitybio, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Deflux$1,321
- GENERAL KIDNEY STONE DISEASE$170
- AMS 700$161
- Rivfloza$122
- DEFLUX METAL NEEDLE$107
- LithoVue$103
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.